Company intelligence / Profile preview

Daxxin

Ownership: Private
Development stage: Other

Overview

Daxxin's lead product is a CE-marked medical device shampoo designed to alleviate symptoms of scalp psoriasis and related conditions. The product is recommended by dermatologists and pharmacists. A post-market clinical follow-up study (NCT06771648) will assess effectiveness and safety in adults with moderate scalp psoriasis; recruitment has not yet started as of April 2025. Products are available through pharmacies and dermatology clinics in Scandinavia.

Therapeutic areas: Dermatology
Modalities: Medical device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Daxxin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Daxxin.

Explore the full profile